Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Issue 2 (February 2017)

• Record Type: Journal Article
• Authors: Gegia, Medea; Winters, Nicholas; Benedetti, Andrea; van Soolingen, Dick; Menzies, Dick
• Is Part Of: Lancet infectious diseases. Volume 17:Issue 2(2017:Feb.)
• Page Start: 223
• Page End: 234
• Publication Date: 2017-02
• Subjects: Communicable diseases -- Periodicals; Infection -- Periodicals; Communicable Diseases -- Periodicals; Infection -- Periodicals; Maladies infectieuses -- Périodiques; Infection -- Périodiques; Communicable diseases; Infection; Periodicals; 616.905
• DOI: 10.1016/S1473-3099(16)30407-8
• Languages: English
• ISSNs: 1473-3099

Abstract

Summary: Background: The results of some reports have suggested that treatment of isoniazid-resistant tuberculosis with the recommended regimens of first-line drugs might be suboptimal. We updated a previous systematic review of treatment outcomes associated with use of first-line drugs in patients with tuberculosis resistant to isoniazid but not rifampicin. Methods: In this systematic review, we updated the results of a previous review to include randomised trials and cohort studies published in English, French, or Spanish to March 31, 2015, containing results of standardised treatment of patients with bacteriologically confirmed isoniazid-resistant tuberculosis (but not multidrug-resistant tuberculosis—ie, not resistant to rifampicin) in whom failure and relapse were bacteriologically confirmed. Results in patients with drug-sensitive tuberculosis included in the same studies were also analysed. We pooled treatment outcomes with random-effects meta-analysis. Findings: We identified 19 cohort studies and 33 trials with 3744 patients with isoniazid-resistant tuberculosis and 19 012 patients with drug-sensitive disease. The pooled rates of failure or relapse, or both, and acquired drug resistance with all drug regimens were 15% (95% CI 12–18) and 3·6% (2–5), respectively, in patients with isoniazid-resistant tuberculosis and 4% (3–5) and 0·6% (0·3–0·9) in those with drug-sensitive tuberculosis. Of patients with initial isoniazid-resistant tuberculosis with acquired drug resistance, 96% (93–99) had acquired multidrug-resistant disease. Treatment of isoniazid-resistant tuberculosis with the WHO standard regimen for new patients resulted in treatment failure, relapse, and acquired multidrug resistance in 11% (6–17), 10% (5–15) and 8% (3–13), respectively; treatment with the standard WHO regimen for previously treated patients resulted in treatment failure in 6% (2–10), relapse in 5% (2–8), and acquisition of multidrug resistance in 3% (0–6). For patients with drug-sensitive disease treated with the standard retreatment regimen the rates were 1% (0–2), 5% (4–7), and 0·3% (0–0·6). Interpretation: Treatment of isoniazid-resistant tuberculosis with first-line drugs resulted in suboptimal outcomes, supporting the need for better regimens. Standardised empirical treatment of new cases could be contributing substantially to the multidrug-resistant epidemic, particularly in settings where the prevalence of isoniazid resistance is high. Funding: Canadian Institutes of Health Research.